Professor Qin Renyi’s team from Tongji Hospital published their latest research on the diagnosis and treatment for pancreatic cancer in Nature. This study is conducted in collaboration with the Southern University of Science and Technology (SUSTech), the CAS Center for Excellence in Molecular Cell Science (CEMCS), and the Salk Institute for Biological Studies.

Pancreatic ductal adenocarcinoma (PDAC), the main type of pancreatic cancer, has a complex tumor microenvironment (TME) and a high fatality rate, severely threatening patients’ lives.

“As a clinician, I often feel frustrated in the face of patients diagnosed with terminal cancer. This often happens due to the lack of effective early diagnosis,” said Qin.

To solve the problem, his team has developed a multidimensional proteomic strategy called TMEPro that analyzes 100 human pancreatic tissue samples in depth, casting new light on the early screening of pancreatic cancer.

This research not only pushes the boundaries of pancreatic cancer studies but also has huge potential for clinical application. Additionally, the new strategy it applies is expected to improve the therapeutic effect and prolong the lifespan of patients.

Written by: Lu Sunjie

Edited by: Yu Kai, Chang Wen, Peng Yumeng